The U.S. Patent and Trademark Office (USPTO) has granted Conduit Pharmaceuticals a patent for AZD1656, its experimental therapy for ANCA-associated vasculitis (AAV) and other autoimmune diseases. The USPTO granted a composition of matter patent, which is a type of patent that relates to novel compounds made from two or…
Disease symptoms among people with ANCA-associated vasculitis (AAV) were found to vary by age at diagnosis and biological sex, according to data from more than 1,100 Scandinavian patients. “We identified significant differences in clinical presentation of the disease between female and male patients and between patients with a young…
The likelihood of disease recurrence in people with anti-neutrophilic cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) varies by disease type, with those with granulomatosis with polyangiitis (GPA) more likely to see their disease come back following successful treatment than people with microscopic polyangiitis (MPA), a study found. Patients with MPA may be…
Lixudebart (ALE.F02), an experimental therapy Alentis Therapeutics is developing to help preserve kidney health in ANCA-associated vasculitis (AAV), showed a favorable safety profile in a Phase 2 clinical trial, the company has announced. A separate study testing lixudebart in people with liver disease also showed a good safety…
Self-reactive antibodies, or autoantibodies, against two proteins — homeostatic iron regulator, or HFE, and synaptotagmin 5, known as SYT5 — appear to be linked to a higher risk of relapse among people with ANCA-associated vasculitis (AAV), according to a new study. These findings suggest that the presence of abnormal…
ADX-097, an experimental tissue-targeted therapy that Q32 Bio is developing for ANCA-associated vasculitis (AAV) and other diseases marked by overactivity of the immune complement system, was well tolerated in a Phase 1 clinical trial involving healthy volunteers. The study’s data also indicated that ADX-097 showed a favorable pharmacological…
Blood tests that look for the anti-neutrophil cytoplasmic autoantibodies (ANCAs) that cause ANCA-associated vasculitis (AAV) may help identify patients with kidney involvement, a study shows. Still, ANCA testing was not as accurate for this purpose as a kidney biopsy, wherein a small piece of kidney tissue is collected…
The production of new B-cells, a type of immune cell that helps fight infections but is also involved in the abnormal immune attacks that drive ANCA-associated vasculitis (AAV), is dysfunctional in people with the autoimmune disease, a study found. The findings could help shed light on the biological underpinnings…
Symptoms and disease manifestations of eosinophilic granulomatosis with polyangiitis (EGPA), a rare type of ANCA-associated vasculitis (AAV), are generally similar between patients with and without ANCAs, the self-reactive antibodies that drive most AAV cases. That’s according to a study analyzing data from a registry of people with vasculitis, or…
Rituximab is superior to other immunosuppressive treatments at preventing post-surgery relapse in granulomatosis with polyangiitis (GPA) patients undergoing surgery to address subglottic stenosis, a common complication that causes airway narrowing. That’s according to a study that analyzed data from 25 GPA patients who were followed for more than…
Get regular updates to your inbox.